Skip to main content
NCBI home page
The Journal of the Royal College of General Practitioners logoLink to The Journal of the Royal College of General Practitioners
. 1980 Jan;30(210):8–19.

James Mackenzie Lecture 1979. The happiness pill?

C R Kay
PMCID: PMC2159386  PMID: 6989989

Full text

PDF

Images in this article

8p8-a
on p.8

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen W. M., Ehrenstein M. 10-NOR-PROGESTERONE, A PHYSIOLOGICALLY ACTIVE LOWER HOMOLOG OF PROGESTERONE. Science. 1944 Sep 15;100(2594):251–252. doi: 10.1126/science.100.2594.251. [DOI] [PubMed] [Google Scholar]
  2. Arntzenius A. C., van Gent C. M., van der Voort H., Stegerhoek C. I., Styblo K. Reduced high-density lipoprotein in women aged 40-41 using oral contraceptives. Consultation Bureau Heart Project. Lancet. 1978 Jun 10;1(8076):1221–1223. doi: 10.1016/s0140-6736(78)92461-3. [DOI] [PubMed] [Google Scholar]
  3. BARR D. P., RUSS E. M., EDER H. A. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med. 1951 Oct;11(4):480–493. doi: 10.1016/0002-9343(51)90183-0. [DOI] [PubMed] [Google Scholar]
  4. Beral V. Cardiovascular-disease mortality trends and oral-contraceptive use in young women. Lancet. 1976 Nov 13;2(7994):1047–1052. doi: 10.1016/s0140-6736(76)90966-1. [DOI] [PubMed] [Google Scholar]
  5. Bradley D. D., Wingerd J., Petitti D. B., Krauss R. M., Ramcharan S. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N Engl J Med. 1978 Jul 6;299(1):17–20. doi: 10.1056/NEJM197807062990104. [DOI] [PubMed] [Google Scholar]
  6. Cheng M. C., Chew S. C., Cheong J., Choo H. T., Ratnam S. S., Belsey M. A., Edstrom K. E. Safety of postabortion sterilisation compared with interval sterilisation. A controlled study. Lancet. 1979 Sep 29;2(8144):682–685. doi: 10.1016/s0140-6736(79)92077-4. [DOI] [PubMed] [Google Scholar]
  7. Edgren R. A., Sturtevant F. M. Potencies of oral contraceptives. Am J Obstet Gynecol. 1976 Aug 15;125(8):1029–1038. doi: 10.1016/0002-9378(76)90804-8. [DOI] [PubMed] [Google Scholar]
  8. GARCIA C. R., PINCUS G., ROCK J. Effects of certain 19-nor steroids on the normal human menstrual cycle. Science. 1956 Nov 2;124(3227):891–893. doi: 10.1126/science.124.3227.891. [DOI] [PubMed] [Google Scholar]
  9. Gordon T., Castelli W. P., Hjortland M. C., Kannel W. B., Dawber T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977 May;62(5):707–714. doi: 10.1016/0002-9343(77)90874-9. [DOI] [PubMed] [Google Scholar]
  10. HERTZ R., TULLNER W., RAFFELT E. Progestational activity of orally administered 17 alpha-ethinyl-19-nortestosterone. Endocrinology. 1954 Feb;54(2):228–230. doi: 10.1210/endo-54-2-228. [DOI] [PubMed] [Google Scholar]
  11. Larsson-Cohn U., Wallentin L., Zador G. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel. Horm Metab Res. 1979 Jul;11(7):437–440. doi: 10.1055/s-0028-1092755. [DOI] [PubMed] [Google Scholar]
  12. Mann J. I., Doll R., Thorogood M., Vessey M. P., Waters W. E. Risk factors for myocardial infarction in young women. Br J Prev Soc Med. 1976 Jun;30(2):94–100. doi: 10.1136/jech.30.2.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Miller G. J., Miller N. E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. doi: 10.1016/s0140-6736(75)92376-4. [DOI] [PubMed] [Google Scholar]
  14. Mortality in women on oral contraceptives. Lancet. 1977 Oct 8;2(8041):757–758. [PubMed] [Google Scholar]
  15. PINCUS G., CHANG M. C., HAFEZ E. S., ZARROW M. X., MERRILL A. Effects of certain 19-nor steroids on reproductive processes in animals. Science. 1956 Nov 2;124(3227):890–891. doi: 10.1126/science.124.3227.890-a. [DOI] [PubMed] [Google Scholar]
  16. Shapiro S. Editorial: Oral contraceptives and myocardial infarction. N Engl J Med. 1975 Jul 24;293(4):195–196. doi: 10.1056/NEJM197507242930410. [DOI] [PubMed] [Google Scholar]
  17. Shelton J. D., Petitti D. Formulation-dependent effect of oral contraceptives on H.D.L.-cholesterol. Lancet. 1978 Sep 23;2(8091):677–677. doi: 10.1016/s0140-6736(78)92783-6. [DOI] [PubMed] [Google Scholar]
  18. Stokes T., Wynn V. Serum-lipids in women on oral contraceptives. Lancet. 1971 Sep 25;2(7726):677–680. doi: 10.1016/s0140-6736(71)92247-1. [DOI] [PubMed] [Google Scholar]
  19. Vessey M. P., McPherson K., Johnson B. Mortality among women participating in the Oxford/Family Planning Association contraceptive study. Lancet. 1977 Oct 8;2(8041):731–733. doi: 10.1016/s0140-6736(77)90236-7. [DOI] [PubMed] [Google Scholar]
  20. Zilcher H., Kaliman J., Müller M. H.D.L. cholesterol in peripheral vascular disease. Lancet. 1979 Mar 10;1(8115):558–559. doi: 10.1016/s0140-6736(79)90986-3. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of the Royal College of General Practitioners are provided here courtesy of Royal College of General Practitioners

RESOURCES